Biopharma & Life Sciences
Arvinas Executive Compensation (FY25)
ARVN · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 25, 2026
239 figures on this page: 233 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Houston: $12,746,981 → $6,534,127 (48.7% lower)
Say-on-pay support: 74.9% → 94.3% (19.4 points higher)
CEO pay ratio: 44:1 → 20:1 (54.5% lower)
Frequently asked questions
Answers drawn from the data on this page.
What was Arvinas' say-on-pay result?
Shareholders supported the say-on-pay proposal with 94.3% of votes cast for or against in favor at the meeting held June 24, 2026 for fiscal 2025.
Which companies are in Arvinas' peer group?
The disclosed peer group names Alector, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Biohaven Ltd. and Cogent Biosciences, Inc., among others.
What is Arvinas' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 20:1, against median employee compensation of $327,724.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Houston President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ian Taylor Former President of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Houston President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Noah Berkowitz Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ian Taylor Former President of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Andrew Saik Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Angela Cacace Chief People Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Houston Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Noah Berkowitz Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Andrew Saik Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Angela Cacace Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ian Taylor Former President of Research and Development Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Saik | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Saik | Option | — | — | — | — | — | — | ◇ |
| Andrew Saik | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Angela Cacace | Option | — | — | — | — | — | — | ◇ |
| Angela Cacace, Ph.D. | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Angela Cacace, Ph.D. | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Ian Taylor, Ph.D. | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Houston | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Noah Berkowitz | Option | — | — | — | — | — | — | ◇ |
| Noah Berkowitz, M.D., Ph.D. | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Noah Berkowitz, M.D., Ph.D. | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Angela Cacace | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Noah Berkowitz | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| John Houston | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Ian Taylor | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Andrew Saik | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Briggs Morrison, M.D Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Sunil Agarwal, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Linda Bain | ◇ | ◇ | ◇ | — | — | — | ◇ |
Leslie V. Norwalk, Esq | ◇ | ◇ | ◇ | — | — | — | ◇ |
Everett Cunningham | ◇ | ◇ | ◇ | — | — | — | ◇ |
Laurie Smaldone Alsup, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Edward Kennedy Jr | ◇ | ◇ | ◇ | — | — | — | ◇ |
John Houston, Ph.D and Randy Teel, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alector, Inc. ALEC
- Arcus Biosciences, Inc. RCUS
- Arrowhead Pharmaceuticals, Inc. ARWR
- Biohaven Ltd. BHVN
- Cogent Biosciences, Inc. COGT
- Crinetics Pharmaceuticals, Inc. CRNX
- Denali Pharmaceuticals, Inc. DNLI
- Erasca, Inc. ERAS
- Intellia Therapeutics, Inc. NTLA
- KalVista Pharmaceuticals, Inc. KALV
- Prothena Corporation plc PRTA
- REGENXBIO, Inc. RGNX
- Relay Therapeutics, Inc. RLAY
- SpringWorks Therapeutics, Inc. SWTX
- Syndax Pharmaceuticals, Inc. SNDX
- Xencor, Inc. XNCR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 24, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 25, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 29, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 16, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 8, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Arvinas disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arvinas sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
239 figures on this page: 233 cited to the filing that reported them, 6 calculated from figures it prints.
233 cited to the filing
6 calculated from the filing
Documents cited
- 0001628280-26-045520
- 0001628280-26-0281562025 Summary Compensation Table · AND DIRECTOR COMPENSATION · Director Compensation · EXECUTIVE AND DIRECTOR COMPENSATION · and 4 more sections
- 0001655759-25-000128
- 0001655759-25-0000752024 Summary Compensation Table · Summary Compensation Table
- 0001655759-24-000070
- 0001655759-24-0000522023 Summary Compensation Table
- 0001655759-23-000073
- 0001655759-22-000020Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-21-186693Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arvinas executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/ARVN (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arvinas and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Arvinas discloses
The companies named in ARVN's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}